IPO
Filter News
Found 17,194 articles
-
CEO Patrik Dahlen purchases Immunovia shares - May 28, 2021
5/28/2021
Immunovia AB announces that Patrik Dahlen, CEO of Immunovia, has purchased 6,860 shares for approximately SEK 675,000 over the stock exchange.
-
Year-end report, May-April 2020/21
5/28/2021
During Elekta's fourth quarter, we drove strong order growth in all regions – both from market growth and market share gain – and we received our 100th Unity order.
-
Beroni Group Issues US$2 Million of Convertible Notes to Fund Research and Development Plans
5/28/2021
Beroni Group, an Australia-based diversified biopharmaceutical enterprise announced that it has raised US$2 million via the issue of convertible notes to an investor in Japan with the following key terms
-
Centessa Announces Pricing of Initial Public Offering - May 28, 2021
5/28/2021
Centessa Pharmaceuticals plc, a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced the pricing of its initial public offering of 16,500,000 American Depositary Shares, each representing one ordinary share at a public offering price of $20.00 per ADS.
-
Hemogenyx Pharmaceuticals PLC announces Total Voting Rights - May 28, 2021
5/28/2021
Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 May 2021 consists of 979,749,321 ordinary shares of 1 pence each, none of which are held in treasury.
-
Dynamics Special Purpose Corp. Announces Closing of $230 Million Initial Public Offering Including Full Exercise of Underwriters’ Over-Allotment Option
5/28/2021
Dynamics Special Purpose Corp. (the “Company”) announced today the closing of its initial public offering of 23,000,000 shares of Class A common stock, which included the full exercise of the underwriters’ over-allotment option of 3,000,000 shares of Class A common stock.
-
WELL's CRH Medical Acquires Majority Stake in Two Anesthesia Practices
5/27/2021
WELL Health Technologies Corp. is pleased to announce its wholly owned subsidiary, CRH Medical Corporation, has completed two accretive transactions whereby the company has acquired a 51% stake in Northern Indiana Anesthesia Associates, LLC and an add-on practice in Bradenton, Florida which will be part of CRH affiliate, FDHS Anesthesia, LLC.
-
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
5/27/2021
Pulmocide Ltd., a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, announced it has raised $92 million in an oversubscribed Series C financing round.
-
AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests Completed
5/27/2021
AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States, announced its unaudited financial results for the first quarter ended March 31, 2021.
-
RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights
5/27/2021
Q1/2021 net revenues of approximately $20.6 million compared to $1.1 million for Q1/2020; Cash balance[i] of approximately $92 million as of March 31, 2021, compared to approximately $115 million as of March 31, 2020
-
CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of $14.5 Million
5/27/2021
CollPlant, a regenerative and aesthetic medicine company, announced financial results for the first quarter ended March 31, 2021 and provided an update on the Company's business developments.
-
DENTSPLY SIRONA Increases Quarterly Cash Dividend By 10%
5/27/2021
DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), announced that its Board of Directors approved a 10% increase in the company’s quarterly dividend rate, from the previous rate of $0.10 per share of common stock to $0.11 per share. The dividend is payable on July 9, 2021 to holders of record as of June 25, 2021.
-
binx health Raises $104 Million in Series E Financing
5/27/2021
binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop, announced the closing of a Series E financing of $104 million.
-
Aptar Releases 2020 Corporate Sustainability Report
5/27/2021
AptarGroup, Inc., a global leader in drug delivery, consumer product dispensing and active material science solutions, released its 2020 Corporate Sustainability Report.
-
Extendicare Announces Voting Results from the 2021 Annual and Special Meeting of Shareholders
5/27/2021
Extendicare Inc. announced the results of matters voted on at its annual and special meeting of shareholders held on May 27, 2021, which included the election as directors of the Company of all of the nominees listed in its management information and proxy circular dated April 15, 2021.
-
Provention Bio Stock Trading Halted Today
5/27/2021
-- FDA Advisory Committee to Review Biologics License Application for PRV-031 for the Delay of Clinical Type 1 Diabetes --
-
InspireMD Announces Warrants Exchange Listing Transfer to NasdaqTickers to be NSPRW and NSPRZ
5/27/2021
InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of Carotid Artery Disease, announced the Company’s warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market.
-
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
5/27/2021
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced the closing of its underwritten public offering of 3,285,714 shares of its common stock at a public offering price of $7.00 per share, which includes 428,571 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
-
MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings
5/27/2021
IRVINE, CA, and HERSTAL, BELGIUM – 27 May 2021 – MDxHealth SA a commercial-stage innovative molecular diagnostics company, held its annual general shareholders' meeting and an extraordinary general shareholders' meeting
-
Singular Genomics Systems, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock - May 27, 2021
5/27/2021
Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, announced the pricing of its upsized initial public offering of 10,200,000 shares of its common stock at an initial public offering price of $22.00 per share.